Advertisement

Placebos and Nocebos in Migraine: Children and Adolescents

  • Vanda FariaEmail author
  • David Borsook
Chapter
First Online:
Part of the Headache book series (HEAD)

Abstract

Harnessing the placebo effect in clinical settings has been one of the goals of placebo research. However, most of the studies have been performed with healthy participants. Evaluating the placebo response constitutes a challenge in many conditions due to their ongoing nature and undulating processes that make interventions more complex in terms of identifying responsivity. Migraine, particularly episodic migraine, provides an ideal disease to evaluate placebo and nocebo responses because of its intermittent nature and the ability to evaluate a number of processes involved in treatment. The approach becomes even more interesting in the pediatric population where suggestibility may be more effective than in adults. In this chapter we present migraine as a model to investigate the impact of placebo and nocebo responsivity, provide a summary of placebo (and nocebo) in the pediatric migraine population, and offer a few suggestions related to the process, the utility, and the ethics of introducing placebo and managing nocebo into the pediatric clinic.

Keywords

Pediatric Children Adolescents Headache Brain function MRI Brain development Architecture Parents Clinic 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Aamodt AH, Stovner LJ, Langhammer A, Hagen K, Zwart JA. Is headache related to asthma, hay fever, and chronic bronchitis? The Head-HUNT Study. Headache. 2007;47(2):204–12.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Annoni M, Miller FG. Placebo effects and the ethics of therapeutic communication: a pragmatic perspective. Kennedy Inst Ethics J. 2016;26(1):79–103.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Antonaci F, Voiticovschi-Iosob C, Di Stefano AL, Galli F, Ozge A, Balottin U. The evolution of headache from childhood to adulthood: a review of the literature. J Headache Pain. 2014;15:15.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Benedetti F, Carlino E, Pollo A. How placebos change the patient’s brain. Neuropsychopharmacology. 2011;36(1):339–54.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Benedetti F. How the doctor’s words affect the patient’s brain. Eval Health Prof. 2002;25(4):369–86.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Benedetti F. Placebo and the new physiology of the doctor-patient relationship. Physiol Rev. 2013;93(3):1207–46.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Benedetti F. Responding to nocebos through observation: social contagion of negative emotions. Pain. 2013;154(8):1165.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Bensing JM, Verheul W. The silent healer: the role of communication in placebo effects. Patient Educ Couns. 2010;80(3):293–9.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Bhugra D, Ventriglio A, Till A, Malhi G. Colour, culture and placebo response. Int J Soc Psychiatry. 2015;61(6):615–7.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Bille B. Migraine and tension-type headache in children and adolescents. Cephalalgia. 1996;16(2):78.PubMedCrossRefGoogle Scholar
  11. 11.
    Bingel U, Wanigasekera V, Wiech K, Ni Mhuircheartaigh R, Lee MC, Ploner M, et al. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med. 2011;3(70):70ra14.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Birnie KA, Chambers CT, Chorney J, Fernandez CV, McGrath PJ. Dyadic analysis of child and parent trait and state pain catastrophizing in the process of children’s pain communication. Pain. 2016;157(4):938–48.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Blankenship SL, Redcay E, Dougherty LR, Riggins T. Development of hippocampal functional connectivity during childhood. Hum Brain Mapp. 2017;38(1):182–201.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Borsook D, Maleki N, Becerra L, McEwen B. Understanding migraine through the lens of maladaptive stress responses: a model disease of allostatic load. Neuron. 2012;73(2):219–34.PubMedCrossRefGoogle Scholar
  15. 15.
    Brascher AK, Kleinbohl D, Holzl R, Becker S. Differential classical conditioning of the nocebo effect: increasing heat-pain perception without verbal suggestions. Front Psychol. 2017;8:2163.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Brown KK, Gallant D. Impacting patient outcomes through design: acuity adaptable care/universal room design. Crit Care Nurs Q. 2006;29(4):326–41.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35(17):6619–29.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Casey BJ, Tottenham N, Liston C, Durston S. Imaging the developing brain: what have we learned about cognitive development? Trends Cogn Sci. 2005;9(3):104–10.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Colloca L, Benedetti F. Nocebo hyperalgesia: how anxiety is turned into pain. Curr Opin Anaesthesiol. 2007;20(5):435–9.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Colloca L, Benedetti F. Placebo analgesia induced by social observational learning. Pain. 2009;144(1–2):28–34.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Colloca L, Grillon C. Understanding placebo and nocebo responses for pain management. Curr Pain Headache Rep. 2014;18(6):419.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Colquhoun D, Novella SP. Acupuncture is theatrical placebo. Anesth Analg. 2013;116(6):1360–3.PubMedCrossRefGoogle Scholar
  23. 23.
    Czerniak E, Biegon A, Ziv A, Karnieli-Miller O, Weiser M, Alon U, Citron A. Manipulating the Placebo response in experimental pain by altering doctor’s performance style. Front Psychol. 2016;7:874.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Danno K, Colas A, Masson JL, Bordet MF. Homeopathic treatment of migraine in children: results of a prospective, multicenter, observational study. J Altern Complement Med. 2013;19(2):119–23.PubMedCrossRefGoogle Scholar
  25. 25.
    Davey G, Sedgwick P, Maier W, Visick G, Strachan DP, HR A. Association between migraine and asthma: matched case-control study. Br J Gen Pract. 2002;52(482):723–7.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–602.CrossRefGoogle Scholar
  27. 27.
    Dodd S, Dean OM, Vian J, Berk M. A review of the theoretical and biological understanding of the nocebo and placebo phenomena. Clin Ther. 2017;39(3):469–76.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Eidlitz-Markus T, Haimi-Cohen Y, Steier D, Zeharia A. Effectiveness of nonpharmacologic treatment for migraine in young children. Headache. 2010;50(2):219–23.PubMedCrossRefGoogle Scholar
  29. 29.
    El-Chammas K, Keyes J, Thompson N, Vijayakumar J, Becher D, Jackson JL. Pharmacologic treatment of pediatric headaches: a meta-analysis. JAMA Pediatr. 2013;167(3):250–8.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Ernst MM, O’Brien HL, Powers SW. Cognitive-behavioral therapy: how medical providers can increase patient and family openness and access to evidence-based multimodal therapy for pediatric migraine. Headache. 2015;55(10):1382–96.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Faria V, Erpelding N, Lebel A, Johnson A, Wolff R, Fair D, Burstein R, Becerra L, Borsook D. The migraine brain in transition: girls vs boys. Pain. 2015;156(11):2212–21.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Faria V, Fredrikson M, Furmark T. Imaging the placebo response: a neurofunctional review. Eur Neuropsychopharmacol. 2008;18(7):473–85.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Faria V, Gingnell M, Hoppe JM, Hjorth O, Alaie I, Frick A, Hultberg S, Wahlstedt K, Engman J, Månsson KNT, Carlbring P, Andersson G, Reis M, Larsson EM, Fredrikson M, Furmark T. Do you believe it? Verbal suggestions influence the clinical and neural effects of escitalopram in social anxiety disorder: a randomized trial. EBioMedicine. 2017;24:179–88.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Faria V, Kossowsky J, Petkov MP, Kaptchuk TJ, Kirsch I, Lebel A, Borsook D. Parental attitudes about placebo use in children. J Pediatr. 2017;181:272–8.e10.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Faria V, Linnman C, Lebel A, Borsook D. Harnessing the placebo effect in pediatric migraine clinic. J Pediatr. 2014;165(4):659–65.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Fernandes R, Ferreira JJ, Sampaio C. The placebo response in studies of acute migraine. J Pediatr. 2008;152(4):527–33, 33.e1.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Finniss DG, Kaptchuk TJ, Miller F, Benedetti F. Biological, clinical, and ethical advances of placebo effects. Lancet. 2010;375(9715):686–95.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Fiorio M, Recchia S, Corra F, Simonetto S, Garcia-Larrea L, Tinazzi M. Enhancing non-noxious perception: behavioural and neurophysiological correlates of a placebo-like manipulation. Neuroscience. 2012;217:96–104.CrossRefGoogle Scholar
  39. 39.
    Francis M. Placebo spectacles-an excellent non pharmacological treatment for pediatric migraine. Cephalalgia. 2013;33:8–255.Google Scholar
  40. 40.
    Galli F, D’Antuono G, Tarantino S, Viviano F, Borrelli O, Chirumbolo A, et al. Headache and recurrent abdominal pain: a controlled study by the means of the Child Behaviour Checklist (CBCL). Cephalalgia. 2007;27(3):211–9.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    German TP, Defeyter MA. Immunity to functional fixedness in young children. Psychon Bull Rev. 2000;7(4):707–12.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Grelotti DJ, Kaptchuk TJ. Placebo by proxy. BMJ. 2011;343:d4345.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Hansen E, Zech N, Meissner K. [Placebo and nocebo: how can they be used or avoided?]. Internist (Berl). 2017;58(10):1102–10.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Harris P, Loveman E, Clegg A, Easton S, Berry N. Systematic review of cognitive behavioural therapy for the management of headaches and migraines in adults. Br J Pain. 2015;9(4):213–24.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Hauser W, Hansen E, Enck P. Nocebo phenomena in medicine: their relevance in everyday clinical practice. Dtsch Arztebl Int. 2012;109(26):459–65.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Ho TW, Fan X, Rodgers A, Lines CR, Winner P, Shapiro RE. Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults. Cephalalgia. 2009;29(7):711–8.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Howick J, Bishop FL, Heneghan C, Wolstenholme J, Stevens S, Hobbs FD, Lewith G. Placebo use in the United kingdom: results from a national survey of primary care practitioners. PLoS One. 2013;8(3):e58247.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Hunter T, Siess F, Colloca L. Socially induced placebo analgesia: a comparison of a pre-recorded versus live face-to-face observation. Eur J Pain. 2014;18(7):914–22.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Isik U, Ersu RH, Ay P, Save D, Arman AR, Karakoc F, Dagli E. Prevalence of headache and its association with sleep disorders in children. Pediatr Neurol. 2007;36(3):146–51.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Kam-Hansen S, Jakubowski M, Kelley JM, Kirsch I, Hoaglin DC, Kaptchuk TJ, Burstein R. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci Transl Med. 2014;6(218):218ra5.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, Kowalczykowski M, Miller FG, Kirsch I, Lembo AJ. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One. 2010;5(12):e15591.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, Jacobson EE, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ. 2008;336(7651):999–1003.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Levinson W, Lesser CS, Epstein RM. Developing physician communication skills for patient-centered care. Health Aff (Millwood). 2010;29(7):1310–8.CrossRefGoogle Scholar
  54. 54.
    Lewis DW, Winner P, Wasiewski W. The placebo responder rate in children and adolescents. Headache. 2005;45(3):232–9.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Lewis DW. Almotriptan for the acute treatment of adolescent migraine. Expert Opin Pharmacother. 2010;11(14):2431–6.PubMedCrossRefGoogle Scholar
  56. 56.
    Lichtenberg P, Heresco-Levy U, Nitzan U. The ethics of the placebo in clinical practice. J Med Ethics. 2004;30(6):551–4.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR. Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev. 2009;(1):CD001218.Google Scholar
  58. 58.
    Lucas S. Initial abortive treatments for migraine headache. Curr Treat Options Neurol. 2002;4(5):343–50.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Maas HJ, Danhof M, Della Pasqua OE. Analysis of the relationship between age and treatment response in migraine. Cephalalgia. 2009;29(7):772–80.PubMedCrossRefGoogle Scholar
  60. 60.
    Malloy KM, Milling LS. The effectiveness of virtual reality distraction for pain reduction: a systematic review. Clin Psychol Rev. 2010;30(8):1011–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Melzack R. From the gate to the neuromatrix. Pain. 1999;(Suppl 6):S121–6.CrossRefGoogle Scholar
  62. 62.
    Merikangas KR, Angst J, Isler H. Migraine and psychopathology. Results of the Zurich cohort study of young adults. Arch Gen Psychiatry. 1990;47(9):849–53.PubMedCrossRefGoogle Scholar
  63. 63.
    Neumann M, Edelhauser F, Kreps GL, Scheffer C, Lutz G, Tauschel D, et al. Can patient-provider interaction increase the effectiveness of medical treatment or even substitute it?--an exploration on why and how to study the specific effect of the provider. Patient Educ Couns. 2010;80(3):307–14.PubMedCrossRefGoogle Scholar
  64. 64.
    Ng QX, Venkatanarayanan N, Kumar L. A systematic review and meta-analysis of the efficacy of cognitive behavioral therapy for the management of pediatric migraine. Headache. 2017;57(3):349–62.PubMedCrossRefGoogle Scholar
  65. 65.
    Oppenheim D. Child, parent, and parent-child emotion narratives: implications for developmental psychopathology. Dev Psychopathol. 2006;18(3):771–90.PubMedCrossRefGoogle Scholar
  66. 66.
    Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med. 2017;376(2):115–24.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med. 2008;5(8):e166.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Rojas-Mirquez JC, Rodriguez-Zuniga MJ, Bonilla-Escobar FJ, Garcia-Perdomo HA, Petkov M, Becerra L, et al. Nocebo effect in randomized clinical trials of antidepressants in children and adolescents: systematic review and meta-analysis. Front Behav Neurosci. 2014;8:375.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Samiee-Zafarghandy S, Mazer-Amirshahi M, van den Anker JN. Trends in paediatric clinical pharmacology data in US pharmaceutical labelling. Arch Dis Child. 2014;99(9):862–5.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Sandler AD, Glesne CE, Bodfish JW. Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder? J Dev Behav Pediatr. 2010;31(5):369–75.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Sartory G, Muller B, Metsch J, Pothmann R. A comparison of psychological and pharmacological treatment of pediatric migraine. Behav Res Ther. 1998;36(12):1155–70.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Shang A, Huwiler-Muntener K, Nartey L, Juni P, Dorig S, Sterne JA, et al. Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy. Lancet. 2005;366(9487):726–32.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Sherman LE, Rudie JD, Pfeifer JH, Masten CL, McNealy K, Dapretto M. Development of the default mode and central executive networks across early adolescence: a longitudinal study. Dev Cogn Neurosci. 2014;10:148–59.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Simmons K, Ortiz R, Kossowsky J, Krummenacher P, Grillon C, Pine D, et al. Pain and placebo in pediatrics: a comprehensive review of laboratory and clinical findings. Pain. 2014;155(11):2229–35.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Simons LE, Goubert L, Vervoort T, Borsook D. Circles of engagement: childhood pain and parent brain. Neurosci Biobehav Rev. 2016;68:537–46.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Smith PB, Benjamin DK Jr, Murphy MD, Johann-Liang R, Iyasu S, Gould B, Califf RM, Li JS, Rodriguez W. Safety monitoring of drugs receiving pediatric marketing exclusivity. Pediatrics. 2008;122(3):e628–33.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Stewart WF, Wood C, Reed ML, Roy J, Lipton RB, Group AA. Cumulative lifetime migraine incidence in women and men. Cephalalgia. 2008;28(11):1170–8.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Strine TW, Okoro CA, McGuire LC, Balluz LS. The associations among childhood headaches, emotional and behavioral difficulties, and health care use. Pediatrics. 2006;117(5):1728–35.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Sun H, Bastings E, Temeck J, Smith PB, Men A, Tandon V, et al. Migraine therapeutics in adolescents: a systematic analysis and historic perspectives of triptan trials in adolescents. JAMA Pediatr. 2013;167(3):243–9.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Thompson JJ, Ritenbaugh C, Nichter M. Reconsidering the placebo response from a broad anthropological perspective. Cult Med Psychiatry. 2009;33(1):112–52.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Thompson-Schill SL, Ramscar M, Chrysikou EG. Cognition without control: when a little frontal lobe goes a long way. Curr Dir Psychol Sci. 2009;18(5):259–63.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Verheul W, Sanders A, Bensing J. The effects of physicians’ affect-oriented communication style and raising expectations on analogue patients’ anxiety, affect and expectancies. Patient Educ Couns. 2010;80(3):300–6.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Vijayakumar N, Whittle S, Dennison M, Yucel M, Simmons J, Allen NB. Development of temperamental effortful control mediates the relationship between maturation of the prefrontal cortex and psychopathology during adolescence: a 4-year longitudinal study. Dev Cogn Neurosci. 2014;9:30–43.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Vogtle E, Barke A, Kroner-Herwig B. Nocebo hyperalgesia induced by social observational learning. Pain. 2013;154(8):1427–33.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci. 2015;16(7):403–18.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Weimer K, Gulewitsch MD, Schlarb AA, Schwille-Kiuntke J, Klosterhalfen S, Enck P. Placebo effects in children: a review. Pediatr Res. 2013;74(1):96–102.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Weisz G, Cambrosio A, Keating P, Knaapen L, Schlich T, Tournay VJ. The emergence of clinical practice guidelines. Milbank Q. 2007;85(4):691–727.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Wendelken C, Ferrer E, Ghetti S, Bailey SK, Cutting L, Bunge SA. Frontoparietal structural connectivity in childhood predicts development of functional connectivity and reasoning ability: a large-scale longitudinal investigation. J Neurosci. 2017;37(35):8549–58.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Wilcox SL, Veggeberg R, Lemme J, Hodkinson DJ, Scrivani S, Burstein R, et al. Increased functional activation of limbic brain regions during negative emotional processing in migraine. Front Hum Neurosci. 2016;10:366.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Wober-Bingol C. Epidemiology of migraine and headache in children and adolescents. Curr Pain Headache Rep. 2013;17(6):341.PubMedCrossRefGoogle Scholar
  91. 91.
    Woo KY. Unravelling nocebo effect: the mediating effect of anxiety between anticipation and pain at wound dressing change. J Clin Nurs. 2015;24(13–14):1975–84.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Yujiro I, Shunji N. A psychosomatic study of contagious dermatitis. Kyushu J Med Sci. 1962;13:335–50.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Center for Pain and the Brain, Boston Children’s Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations

Cite chapter

Buy options